The ability to analyse DNA has had an important impact on our understanding of genetic disorders. Many genes have now been cloned and sequenced and the mutations that cause disease identified. Many other genetic disorders, for which the genes are not yet isolated, have been mapped to particular chromosomal locations, and this permits predictive testing with linked DNA markers. It has been estimated that the entire human genome will be mapped and all the important genes sequenced by the end of the century. This is not unrealistic and promises to be of enormous benefit to families with genetic disorders and to potential gene carriers.
International meetings on human gene mapping, inaugurated in 1973, are held every two years and mark current progress. At the first meeting the total number of autosomal genes whose chromosomal location had been identified was 64. The corresponding number of mapped genes had risen to 928 by the ninth meeting in 1987. This tremendous increase reflects the addition of various molecular biological approaches to those of more traditional somatic cell genetics. The total number of mapped X linked loci has also risen, from 155 in 1973 to 308 in 1987. Single copy anonymous DNA segments, which may be used as DNA markers for genetic disorders, number more than 1500 for autosomes and over 300 for the X chromosome. Many of these are clinically useful probes that can be applied both to detecting carriers and to prenatal diagnosis.
In this concluding article some of the ways in which molecular techniques can be applied clinically are illustrated with selected genetic disorders as examples. In most genetic conditions amenable to prenatal diagnosis by DNA analysis studies must be performed on the family first to determine whether there is a DNA variation that gives an informative pattern, and certain key relatives must be available for testing to make prediction possible. Because chorionic villus sampling is performed at eight to nine weeks of gestation counselling and investigating a family before pregnancy is important to ensure that a couple have time to make fully informed decisions. The haemoglobinopathies constitute the most common autosomal disorders world wide and have profound effects on the provision of health care in some developing countries. They were among the first disorders to be analysed at a molecular DNA level, partly because the structure of haemoglobin was already well defined and also because fairly pure messenger RNA could be extracted from reticulocytes and used to produce complementary DNA probes. The globin gene clusters on chromosome 16 include two cc globin genes and on chromosome 11 a i globin gene.
Various mutations in the P3 globin gene cause structural alterations in haemoglobin, the most important being the point mutation that produces haemoglobin S and causes sickle cell anaemia. Direct detection of the point mutation (described in the previous chapter) permits early prenatal diagnosis by analysis of DNA extracted from chorionic villus material. The thalassaemias are due to a reduced rate of production of one or more globin chains, leading to an imbalance in their production. In a thalassaemia production of a globin chains may be absent (aO) or reduced (a+). In the &°thalassaemia trait both a globin genes are deleted from one chromosome and in the homozygous state all four genes are deleted. In the ca thalassaemia trait only one a globin gene is inactivated, either by deletion or mutation, and the other is intact. Deleted genes can be detected directly in the homozygous state by failure of hybridisation with a globin gene probes. n In 13 thalassaemia over 30 different mutations causing the disorder have been identified, which result in ,13 and ,+ types depending on whether the production of 13 globin chains is absent or reduced. Major gene deletions are unusual in ,B thalassaemia, and most mutations entail point mutations or small deletions or insertions. To offer prenatal diagnosis by DNA analysis each individual family must be studied to determine the nature of the mutation. Particular mutations are common in certain populations, and specific oligonucleotide probes are available for prenatal diagnosis in many cases.
Cystic fibrosis is the commonest autosomal recessive disorder in northern Europeans and remains incurable, although survival is improved with supportive treatment. Detection of carriers in the population may soon be possible, but at present prevention depends largely on prenatal diagnosis being offered to couples who already have an affected child. The Brock test has been available for several years and predicts the likelihood of cystic fibrosis in a fetus at high risk by measuring enzyme activities of the microvilli in amniotic fluid. Early prenatal diagnosis is now possible by DNA analysis of chorionic villus material. Huntington's chorea is an autosomal dominant condition and is one ofthe most devastating genetic disorders, with the onset of involuntary movements and dementia being variable but commonly occurring between the ages of 35 and 55. The gene has not yet been cloned but was found to be linked to a probe called G8 in family studies in 1983, which localised the gene to the short arm of chromosome 4. The G8 probe detects polymorphisms with the restriction enzyme Hind III, and the four haplotypes, designated A, B, C, and D, can be tracked through affected families. Other linked probes are also now available and predictive testing for a person at risk is possible if the family structure is suitable and the marker pattern in the family is informative. People at risk, however, may not want predictive testing in the absence of any effective treatment. The potential for predictive testing raises many important ethical issues. Careful counselling before and after such tests is essential to ensure that the patient can cope with possible bad news from a test.
A major concern of many people at risk of developing the disease is that they may transmit the disorder to their children. A prenatal test can be performed that indicates the risk to a fetus without predicting the genetic state ofthe parent. The principle ofthe test is that it determines whether the fetus has inherited a chromosome from the affected or unaffected grandparent through the parent at risk. A chromosome from the affected grandparent confers a 50% risk (the same as the risk to the parent). A chromosome inherited from the unaffected grandparent reduces the risk to that associated with the chance of recombination having occurred between the gene for the;disease and the probe being used. One potential problem with this type of test is that if a pregnancy identified as being at 50% risk continues to term and the parent subsequently develops Huntington's chorea this indicates that the child has probably also inherited the gene and will develop the disorder. Duchenne muscular dystrophy was first described in 1861 and the X linked pattern ofinheritance reported in 1943. A milder form of X linked muscular dystrophy identified by Becker in 1955 is now known to be due to a defect in the same gene. Duchenne muscular dystrophy has been reported in girls who have one X chromosome disrupted by a translocation between it and an autosome, with the normal X chromosome being preferentially inactivated. The site of the breakpoint in the cases of the chromosomal translocation is always located in the Xp2 1 band, which suggested that this was the location of the Duchenne gene. DNA probes identified from this region were shown to be linked to Duchenne Several probes detect restriction fragment length polymorphisms (RFLPs) within the dystrophin gene. The variant bands identified on autoradiography can be used to track the disease gene through a family and make predictions about genetic state in female relatives and male fetuses at risk. As the dystrophin gene is so large (consisting of two million base pairs) and mutations causing muscular dystrophy may occur throughout the gene the gene mutation in a particular family may be a considerable distance from the RFLP site detected by the probe. Recombination between the two sites during gametogenesis may separate the loci so that absolute prediction about transmission of the mutation from parent to child cannot be made from RFLP studies. In family studies 5% recombination is observed and the prediction of genetic state can therefore be made with 95% accuracy.
About 60-70% ofmales with Duchenne and Becker's muscular dystrophy have deletions of coding sequences in the dystrophin gene as shown by hybridisation with complementary DNA probes. This not only confirms the clinical diagnosis, which can be difficult in mild, sporadic cases, but also provides a definitive prenatal diagnostic test in families in which an affected boy has a gene deletion. Chorionic villus sampling in pregnancies at risk allows fetal sexing to be performed by chromosomal and DNA analysis and in male fetuses the presence or absence of a deletion can be determined. This allows unaffected male pregnancies to continue to term, which was not possible when only fetal sexing was available. Different deletions are seen in different families, and patterns are emerging that correspond to the Duchenne and Becker's forms of muscular dystrophy; this helps to distinguish between the two disorders in sporadic cases in young boys. Deletions causing a frame shift completely disrupt dystrophin production or function and cause Duchenne muscular dystrophy whereas deletions that do not disrupt the reading frame allow a modified protein to be produced, resulting in the milder Becker's form. Another example of deletion and RFLP analysis is shown in the autoradiograph opposite. The affected boy again has a gene deletion detected by probe p20 (lane C). His mother (lane A) is apparently homozygous for allele 2. One of the boy's sisters (lane E) has inherited an X chromosomal band from her father (lane B) but not her mother. The explanation of this apparent "non-maternity" is that the daughter has inherited a deleted gene from her mother, and this indicates that they are both carriers. The other sister (lane D) has inherited a paternal and a maternal band. The maternal band corresponds to the non-deleted gene, and this sister is therefore not a carrier.
DNA analysis has proved to be extremely valuable in investigating families with Duchenne and Becker's muscular dystrophy. Not only can many carriers be identified and offered definitive prenatal diagnosis but female relatives at low risk can commonly be identified and reassured. Several difficulties are still encountered: family studies are required and predictive tests may not be possible if the affected boy is no longer living; occasional families have uninformative DNA patterns with the currently available probes; and calculations are often complex. In sporadic cases the mother of an affected boy cannot be given a negligible risk because of the possibility of germline mosaicism, and even if population screening for carriers becomes possible the disorder will not be eradicated because of the frequency with which new mutations occur. 
